---
title: "Ivonescimab in EGFR-mutated non-small-cell lung cancer: Clinical evidence"
description: "Formulary evidence on Ivonescimab in EGFR-mutated non-small-cell lung cancer: Clinical evidence. Covers HARMONi, HARMONi-A, AK112-201, MARIPOSA-2, KEYNOTE-789, CheckMate 722, and 7 further headings. 157 evidence topics quoted from 29 sources."
canonical: "https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:23-05:00"
---

# Ivonescimab in EGFR-mutated non-small-cell lung cancer: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 HARMONi

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Comparative efficacy and safety objective

> “efficacy and safety”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Enrollment interval

> “Jan 25, 2022, to Oct 1, 2024”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### HARMONi: study design

> “HARMONi is a randomised, placebo-controlled, double-blind, phase 3 trial done at 114 cancer centres and hospitals across Asia, Europe, and North America.”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### HARMONi: target population

> “Patients with EGFR+ Non-squamous NSCLC Who Have Progressed After 3rd-Generation EGFR-TKI (osimertinib)”

Source: [Summit Therapeutics HARMONi trial page](https://smmttx.com/clinical-trials/harmoni-clinical-trial/default.aspx)

<a id="topic-3.1.1.4-2"></a>

###### HARMONi: central nervous system eligibility

> “No symptomatic metastases of the central nervous system”

Source: [Summit Therapeutics HARMONi trial page](https://smmttx.com/clinical-trials/harmoni-clinical-trial/default.aspx)

<a id="topic-3.1.1.4-3"></a>

###### ECOG performance status eligibility

> “0 or 1”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Induction and maintenance regimens

| Treatment phase | Quoted regimen |
| --- | --- |
| Initial treatment | “Ivonescimab 20 mg/kg Q3W” “+Pemetrexed 500 mg/m² Q3W” “+Carboplatin AUC 5 Q3W” “4 cycles (3 weeks/cycle)” |
| Maintenance | “Ivonescimab 20 mg/kg Q3W” “+Pemetrexed 500 mg/m² Q3W” |

Source: [Summit Therapeutics HARMONi enrollment fact sheet (2025)](https://s206.q4cdn.com/652410165/files/doc_downloads/fact-sheets/MAT-SMT112-0070_-HARMONi-Patient-Enrollment-2-pager-Public-April2025-2.pdf)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Progression-free Survival as a Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoints

> “progression-free survival”
> “overall survival”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="topic-3.1.1.6.1-2"></a>

###### Regulatory rationale for progression-free survival

> “PFS can reflect tumor growth and be assessed before the determination of a survival benefit.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### HARMONi: randomized population

> “438 patients”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="topic-3.1.1.7.1-2"></a>

###### HARMONi: primary progression-free survival analysis population

> “(N=345; median follow-up 22.3 months)”

Source: [IASLC (2025)](https://www.iaslc.org/iaslc-news/press-release/ivonescimab-plus-chemotherapy-improves-progression-free-survival-patients)

<a id="topic-3.1.1.7.1-3"></a>

###### Primary overall survival significance boundary

> “p-value of 0.0448”

Source: [Summit Therapeutics HARMONi longer-term follow-up announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Longer-Term-Follow-Up-of-Western-Patients-Showed-Improving-Favorable-Trend-in-Overall-Survival-in-Global-Phase-III-HARMONi-Clinical-Trial-for-Ivonescimab-Plus-Chemotherapy-in-2L-EGFRm-NSCLC/default.aspx)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### HARMONi: inclusion of HARMONi-A patients in the planned analysis

> “As a reminder, the HARMONi analysis will include all patients from the HARMONi-A trial who previously received a 3rd generation TKI.”

Source: [Summit Therapeutics HARMONi enrollment completion announcement (2024)](https://smmttx.com/news/press-releases/news-details/2024/Summit-Therapeutics-Announces-Completion-of-Enrollment-in-Its-Phase-III-HARMONi-Trial-in-2L-EGFRm-NSCLC-10-03-2024-12-00-AM/default.aspx)

<a id="topic-3.1.1.7.2-2"></a>

###### Minimum exposure for the safety analysis

> “at least one dose”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Randomized participants per group

> “219 per group”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### HARMONi: geographic representation

> “Approximately 38% of patients were randomized from western countries (ex-Asia)”

Source: [Summit Therapeutics HARMONi progression-free survival announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Ivonescimab-Plus-Chemotherapy-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Progression-Free-Survival-in-Patients-with-EGFR-Mutant-Non-Small-Cell-Lung-Cancer-after-EGFR-TKI-Therapy-in-Global-Study/default.aspx)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### HARMONi: primary progression-free survival

> “Median PFS was 6.8 months (95% CI: 5.7–7.1) versus 4.4 months (95% CI: 4.1–5.5).”

Source: [IASLC (2025)](https://www.iaslc.org/iaslc-news/press-release/ivonescimab-plus-chemotherapy-improves-progression-free-survival-patients)

<a id="topic-3.1.1.8.3-2"></a>

###### HARMONi: progression-free survival hazard ratio

> “a hazard ratio of 0.52 (95% CI: 0.41 – 0.66; p<0.00001)”

Source: [Summit Therapeutics HARMONi progression-free survival announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Ivonescimab-Plus-Chemotherapy-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Progression-Free-Survival-in-Patients-with-EGFR-Mutant-Non-Small-Cell-Lung-Cancer-after-EGFR-TKI-Therapy-in-Global-Study/default.aspx)

<a id="topic-3.1.1.8.3-3"></a>

###### HARMONi: overall response rate

> “(44.7% vs. 34.2%)”

Source: [IASLC (2025)](https://www.iaslc.org/iaslc-news/press-release/ivonescimab-plus-chemotherapy-improves-progression-free-survival-patients)

<a id="topic-3.1.1.8.3-4"></a>

###### HARMONi: primary overall survival analysis, median survival

| Ivonescimab plus chemotherapy | Placebo plus chemotherapy |
| --- | --- |
| “16.8 months” | “14.0 months” |

Source: [Summit Therapeutics HARMONi updated overall survival announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Plus-Chemotherapy-Shows-Consistent-Favorable-Overall-Survival-Results-in-Western-and-Asian-Patients-in-Updated-Analysis-from-Global-Phase-III-HARMONi-Study/default.aspx)

<a id="topic-3.1.1.8.3-5"></a>

###### HARMONi: primary overall survival analysis, statistical result

> “an OS hazard ratio of 0.79 (95% CI: 0.62 – 1.01; p=0.057), which was not statistically significant.”

Source: [Summit Therapeutics HARMONi-A overall survival announcement (2025)](https://www.smmttx.com/news/press-releases/news-details/2025/Ivonescimab-Plus-Chemotherapy-Demonstrates-a-Statistically-Significant-Benefit-in-Overall-Survival-with-a-Hazard-Ratio-of-0-74-in-2L-Treatment-of-Patients-with-EGFRm-NSCLC-in-HARMONi-A-Study-Conducted-by-Akeso-in-China/default.aspx)

<a id="topic-3.1.1.8.3-6"></a>

###### HARMONi: updated overall survival analysis

> “A hazard ratio of 0.76 was observed in both the full intention-to-treat population and the subgroup of western patients.”

Source: [Summit Therapeutics HARMONi updated overall survival announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Plus-Chemotherapy-Shows-Consistent-Favorable-Overall-Survival-Results-in-Western-and-Asian-Patients-in-Updated-Analysis-from-Global-Phase-III-HARMONi-Study/default.aspx)

<a id="topic-3.1.1.8.3-7"></a>

###### HARMONi: intracranial progression-free survival, baseline brain metastases

> “10.1 months compared to 6.5 months for chemotherapy (HR 0.53 (0.33-0.84); nominal p=0.0068).”

Source: [Summit Therapeutics ELCC 2026 presentations announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Multiple-Ivonescimab-Data-Sets-from-Phase-III-Studies-in-Advanced-NSCLC-Patient-Populations-to-be-Featured-at-ELCC-2026/default.aspx)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Exploratory EORTC QLQ-C30 assessment

> “An exploratory endpoint was health-related quality-of-life (HRQOL) assessment using the European Organisation for Cancer Research and Treatment—Core 30 Questionnaire (EORTC QLQ-C30)”
> “Overall, the addition of ivonescimab to chemotherapy had no detrimental impact on patient HRQOL; no clinically meaningful differences (≥10 points) between treatment groups were observed for EORTC QLQ-C30 symptoms”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

Additional sources: [Leighl et al. (2026)](https://www.esmoopen.com/article/S2059-7029%2826%2900269-3/fulltext)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Summary

The sponsor table retains randomized arm sizes of 219. The primary publication reports safety denominators of 218 treated participants per arm.

Source: [Summit Therapeutics HARMONi longer-term follow-up announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Longer-Term-Follow-Up-of-Western-Patients-Showed-Improving-Favorable-Trend-in-Overall-Survival-in-Global-Phase-III-HARMONi-Clinical-Trial-for-Ivonescimab-Plus-Chemotherapy-in-2L-EGFRm-NSCLC/default.aspx); [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="topic-3.1.1.8.5-2"></a>

###### HARMONi: safety

| Adverse event category | “Ivonescimab + Chemo(n=219)” | “Placebo + Chemo(n=219)” |
| --- | --- | --- |
| “TRAEs Grade 3+” | “50.0%” | “42.2%” |
| “TRAEs Leading to Drug Discontinuation” | “7.3%” | “5.0%” |
| “TRAEs Leading to Death” | “1.8%” | “2.3%” |

Source: [Summit Therapeutics HARMONi longer-term follow-up announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Longer-Term-Follow-Up-of-Western-Patients-Showed-Improving-Favorable-Trend-in-Overall-Survival-in-Global-Phase-III-HARMONi-Clinical-Trial-for-Ivonescimab-Plus-Chemotherapy-in-2L-EGFRm-NSCLC/default.aspx)

<a id="topic-3.1.1.8.5-3"></a>

###### Treated participants per arm in the primary safety analysis

> “218”

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The primary PFS analysis included 345 participants, not all 438 randomized participants. The primary OS comparison did not meet its significance boundary. The later HR of 0.76 is a follow-up result and does not replace the primary OS test. Intracranial findings were exploratory and outside the multiplicity-controlled hierarchy. Because the analysis included third-generation TKI-treated participants from HARMONi-A, the two trials should not be pooled as independent populations. The comparator was chemotherapy alone, not another active post-TKI combination.

Source: [Le et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42636833/); [IASLC (2025)](https://www.iaslc.org/iaslc-news/press-release/ivonescimab-plus-chemotherapy-improves-progression-free-survival-patients); [Summit Therapeutics HARMONi longer-term follow-up announcement (2025)](https://smmttx.com/news/press-releases/news-details/2025/Longer-Term-Follow-Up-of-Western-Patients-Showed-Improving-Favorable-Trend-in-Overall-Survival-in-Global-Phase-III-HARMONi-Clinical-Trial-for-Ivonescimab-Plus-Chemotherapy-in-2L-EGFRm-NSCLC/default.aspx); [Summit Therapeutics HARMONi-A overall survival announcement (2025)](https://www.smmttx.com/news/press-releases/news-details/2025/Ivonescimab-Plus-Chemotherapy-Demonstrates-a-Statistically-Significant-Benefit-in-Overall-Survival-with-a-Hazard-Ratio-of-0-74-in-2L-Treatment-of-Patients-with-EGFRm-NSCLC-in-HARMONi-A-Study-Conducted-by-Akeso-in-China/default.aspx); [Summit Therapeutics HARMONi updated overall survival announcement (2026)](https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Plus-Chemotherapy-Shows-Consistent-Favorable-Overall-Survival-Results-in-Western-and-Asian-Patients-in-Updated-Analysis-from-Global-Phase-III-HARMONi-Study/default.aspx); [Le et al. (2026a)](https://s206.q4cdn.com/652410165/files/doc_downloads/publications/2026/03/3-Intracranial-Efficacy-of-Ivonescimab-Plus-Chemotherapy-in-Epidermal-Growth-Factor-Receptor-EGFR-Tyrosine-Kinase-Inhibitor-Resistant-EGFR-Mu.pdf); [Summit Therapeutics HARMONi enrollment completion announcement (2024)](https://smmttx.com/news/press-releases/news-details/2024/Summit-Therapeutics-Announces-Completion-of-Enrollment-in-Its-Phase-III-HARMONi-Trial-in-2L-EGFRm-NSCLC-10-03-2024-12-00-AM/default.aspx)

<a id="topic-3.1.1.9-2"></a>

###### HARMONi: intracranial analysis limitations

> “Intracranial endpoints were evaluated in prespecified exploratory analyses of HARMONi and were not part of the primary multiplicity-controlled testing hierarchy”

Source: [Le et al. (2026a)](https://s206.q4cdn.com/652410165/files/doc_downloads/publications/2026/03/3-Intracranial-Efficacy-of-Ivonescimab-Plus-Chemotherapy-in-Epidermal-Growth-Factor-Receptor-EGFR-Tyrosine-Kinase-Inhibitor-Resistant-EGFR-Mu.pdf)

<a id="heading-3.1.2"></a>

#### 3.1.2 HARMONi-A

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Comparison against chemotherapy alone after EGFR-TKI progression

> “To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non–small cell lung cancer with the epidermal growth factor receptor (EGFR) variant.”
> “For patients with non–small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited.”

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### HARMONi-A: setting

| Evidence element | Direct quotation |
| --- | --- |
| Setting | “55 sites in China” |

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Study masking

> “Double-blind”

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### ECOG performance status eligibility

> “0 or 1”

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Study treatment combinations

> “ivonescimab plus chemotherapy or placebo plus chemotherapy”

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using IRRC-assessed Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint

> “IRRC-assessed PFS”

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

Additional sources: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### HARMONi-A: enrollment

| Evidence element | Direct quotation |
| --- | --- |
| Enrollment | “322” |

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="topic-3.1.2.7.1-2"></a>

###### Planned statistical design

| Design element | Quoted value |
| --- | --- |
| Planned participants | “320” |
| Planned PFS events | “225” |
| Power | “89%” |
| Target hazard ratio | “0.65” |
| Interim significance boundary | “.024” |

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Efficacy analysis population

> “all randomized patients”

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="topic-3.1.2.7.2-2"></a>

###### Time-to-event estimation method

> “Kaplan-Meier method”

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Screened participants

> “501”

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Median age at the final survival analysis

> “59.4 years”

Source: [HARMONi-A Study Investigators (2026)](https://pubmed.ncbi.nlm.nih.gov/42307937/)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### HARMONi-A: initial progression-free survival

| Evidence element | Direct quotation |
| --- | --- |
| Median progression-free survival, ivonescimab plus chemotherapy, months | “7.1 (95% CI, 5.9-8.7)” |
| Median progression-free survival, placebo plus chemotherapy, months | “4.8 (95% CI, 4.2-5.6)” |
| Progression-free survival comparison | “hazard ratio [HR], 0.46 [95% CI, 0.34-0.62]; P < .001” |

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="topic-3.1.2.8.3-2"></a>

###### HARMONi-A: final overall survival

| Evidence element | Direct quotation |
| --- | --- |
| Median overall survival, ivonescimab plus chemotherapy versus placebo plus chemotherapy | “16.8 months vs 14.1 months” |
| Overall survival comparison | “hazard ratio, 0.74; 95% CI, 0.58-0.95; P = .02” |

Source: [HARMONi-A Study Investigators (2026)](https://pubmed.ncbi.nlm.nih.gov/42307937/)

<a id="topic-3.1.2.8.3-3"></a>

###### HARMONi-A: objective response and prespecified subgroups

> “The prespecified subgroup analysis showed progression-free survival benefit favoring patients receiving ivonescimab over placebo across almost all subgroups, including patients whose disease progressed while receiving third-generation EGFR-TKI therapy (HR, 0.48 [95% CI, 0.35-0.66]) and those with brain metastases (HR, 0.40 [95% CI, 0.22-0.73]).”
> “The objective response rate was 50.6% (95% CI, 42.6%-58.6%) with ivonescimab and 35.4% (95% CI, 28.0%-43.3%) with placebo (difference, 15.6% [95% CI, 5.3%-26.0%]; P = .006).”

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### HARMONi-A: final safety analysis

| Evidence element | Direct quotation |
| --- | --- |
| Safety outcome | “Grade 3 or higher treatment-emergent adverse events” |
| Ivonescimab plus chemotherapy | “67.1%” |
| Placebo plus chemotherapy | “54.7%” |

Source: [HARMONi-A Study Investigators (2026)](https://pubmed.ncbi.nlm.nih.gov/42307937/)

<a id="topic-3.1.2.8.5-2"></a>

###### HARMONi-A: adverse events of special interest at the primary analysis

> “Grade 3 or higher treatment-emergent adverse events occurred in 99 patients (61.5%) in the ivonescimab group vs 79 patients (49.1%) in the placebo group, the most common of which were chemotherapy-related.”
> “Grade 3 or higher immune-related adverse events occurred in 10 patients (6.2%) in the ivonescimab group vs 4 (2.5%) in the placebo group.”
> “Grade 3 or higher vascular endothelial growth factor–related adverse events occurred in 5 patients (3.1%) in the ivonescimab group vs 4 (2.5%) in the placebo group.”

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

All 322 participants were enrolled at sites in China, which limits direct geographic generalization. The initial publication reported PFS; the subsequent final OS publication should be considered separately rather than treating early survival immaturity as a continuing limitation. The final OS comparison favored ivonescimab, but grade 3 or higher TEAEs were reported in 67.1% versus 54.7%. HARMONi incorporates an overlapping third-generation TKI-treated population, so its findings are not wholly independent replication.

Source: [HARMONi-A Study Investigators (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11337070/); [HARMONi-A Study Investigators (2026)](https://pubmed.ncbi.nlm.nih.gov/42307937/); [Summit Therapeutics HARMONi enrollment completion announcement (2024)](https://smmttx.com/news/press-releases/news-details/2024/Summit-Therapeutics-Announces-Completion-of-Enrollment-in-Its-Phase-III-HARMONi-Trial-in-2L-EGFRm-NSCLC-10-03-2024-12-00-AM/default.aspx)

<a id="topic-3.1.2.9-2"></a>

###### HARMONi-A correspondence: methodology and interpretation concerns

> “some concerns about the methodology and interpretation”

Source: [Cheng et al. (2025)](https://jamanetwork.com/journals/jama/fullarticle/2827784)

<a id="topic-3.1.2.9-3"></a>

###### HARMONi-A correspondence: authors’ reply

> “our study reported progression-free survival as the primary end point.”

Source: [Fang et al. (2025)](https://jamanetwork.com/journals/jama/fullarticle/2827782)

Additional sources: [Liu et al. (2025)](https://jamanetwork.com/journals/jama/fullarticle/2827783)

<a id="heading-3.1.3"></a>

#### 3.1.3 AK112-201

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Study objective

> “efficacy and safety”

Source: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study locations

> “11 hospitals in China”

Source: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Phase II study: design

| Evidence element | Direct quotation |
| --- | --- |
| Design | “open-label, multicenter, phase II” |

Source: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Phase II study: EGFR-mutated cohort

| Evidence element | Direct quotation |
| --- | --- |
| Population | “The participants in cohort 2 had advanced NSCLC with EGFR-sensitive mutations” |

Source: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Cohort 2 induction treatment

> “pemetrexed plus AK112 and carboplatin for four cycles”

Source: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Objective Response Rate as a Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary efficacy outcome

> “investigator-assessed objective response rate (ORR)”

Source: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

Additional sources: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Participants in the EGFR-mutated cohort

> “19”

Source: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

Additional sources: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

Additional sources: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

Additional sources: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Phase II study: EGFR-mutated cohort efficacy

| Evidence element | Direct quotation |
| --- | --- |
| Objective response rate, cohort 2 | “68.4% (13/19) [95% CI, 43.4-87.4]” |
| Median progression-free survival, cohort 2, months | “8.5 [95% CI, 5.5-NE]” |

Source: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Study-wide severe white blood cell count decrease

> “7 (8.4%)”

Source: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The EGFR-mutated cohort contained 19 participants in an open-label study without a concurrent randomized comparator. Its ORR confidence interval was 43.4% to 87.4%, and the PFS upper confidence limit was not estimable. These results do not establish a comparative survival benefit. The study-wide safety percentage is not an EGFR-cohort-specific estimate.

Source: [Zhao et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10430160/)

<a id="heading-3.1.4"></a>

#### 3.1.4 MARIPOSA-2

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

Additional sources: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Geographic scope

> “global”

Source: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Trial phase

> “phase III”

Source: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Eligible EGFR alterations

> “exon 19 deletions or L858R”

Source: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Randomized treatment groups

| Group | Quoted regimen |
| --- | --- |
| Combination with lazertinib | “amivantamab-lazertinib-chemotherapy” |
| Control | “chemotherapy” |
| Combination without lazertinib | “amivantamab-chemotherapy” |

Source: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="topic-3.1.4.5-2"></a>

###### Chemotherapy backbone

> “carboplatin-pemetrexed”

Source: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Dual primary comparison endpoint

> “progression-free survival (PFS)”

Source: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

Additional sources: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Randomized participants

> “657”

Source: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

Additional sources: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

Additional sources: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

Additional sources: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Median progression-free survival

| Amivantamab plus chemotherapy, months | Amivantamab plus lazertinib and chemotherapy, months | Chemotherapy, months |
| --- | --- | --- |
| “6.3” | “8.3” | “4.2” |

Source: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Predominant adverse-event categories

> “hematologic, EGFR-, and MET-related toxicities.”

Source: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

This trial compares amivantamab-based combinations with chemotherapy, not with ivonescimab. Its PFS results therefore cannot establish the relative efficacy of amivantamab and ivonescimab. Toxicities span hematologic, EGFR-related, and MET-related categories; a PFS comparison alone does not summarize the full benefit-risk balance.

Source: [Passaro et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879444/)

<a id="heading-3.1.5"></a>

#### 3.1.5 KEYNOTE-789

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

Additional sources: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Analysis data cutoffs

| Analysis | Quoted date |
| --- | --- |
| Final PFS testing | “December 3, 2021” |
| Final OS analysis | “January 17, 2023” |

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Comparator trial: KEYNOTE-789

> “Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab”

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Eligible EGFR alterations

> “DEL19 or L858R”

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Experimental and control additions to chemotherapy

> “pembrolizumab 200 mg”
> “placebo”

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Progression-free Survival as a Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Dual primary endpoints

> “PFS”
> “OS”

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

Additional sources: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Randomized participants by group

| Pembrolizumab plus chemotherapy | Placebo plus chemotherapy |
| --- | --- |
| “245” | “247” |

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Prespecified efficacy threshold and PFS test

| Statistical quantity | Quoted value |
| --- | --- |
| One-sided efficacy boundary for PFS and OS | “.0117” |
| Observed one-sided PFS P value | “.0122” |

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

Additional sources: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Median survival outcomes

| Outcome | Pembrolizumab plus chemotherapy, months | Placebo plus chemotherapy, months |
| --- | --- | --- |
| PFS | “5.6” | “5.5” |
| OS | “15.9” | “14.7” |

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="topic-3.1.5.8.3-2"></a>

###### Comparator trial: primary efficacy conclusion

> “did not significantly prolong PFS or OS versus placebo plus chemotherapy”

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Grade 3 or higher treatment-related adverse events

| Pembrolizumab plus chemotherapy | Placebo plus chemotherapy |
| --- | --- |
| “43.7%” | “38.6%” |

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

The PFS P value of 0.0122 did not meet the prespecified one-sided boundary of 0.0117. Neither primary efficacy endpoint was met. These results concern pembrolizumab plus chemotherapy, not ivonescimab, and cannot determine the effect of simultaneous PD-1 and VEGF inhibition.

Source: [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11608596/)

<a id="heading-3.1.6"></a>

#### 3.1.6 CheckMate 722

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

Additional sources: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

Additional sources: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Masking design

> “open-label”

Source: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

Additional sources: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Nivolumab dose with chemotherapy

> “360 mg”

Source: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Progression-free Survival as the Primary Endpoint

Additional sources: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/); [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Planned and randomized participants

| Quantity | Quoted count |
| --- | --- |
| Original enrollment target | “500” |
| Revised enrollment target | “270” |
| Randomized participants | “294” |

Source: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Estimated statistical power with observed PFS events

> “76%”

Source: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### Treated participants

| Nivolumab plus chemotherapy | Chemotherapy |
| --- | --- |
| “141” | “143” |

Source: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

Additional sources: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Median progression-free survival

| Nivolumab plus chemotherapy, months | Chemotherapy, months |
| --- | --- |
| “5.6” | “5.4” |

Source: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="topic-3.1.6.8.3-2"></a>

###### Comparator trial: CheckMate 722

> “Nivolumab plus chemotherapy did not significantly improve PFS versus chemotherapy in patients with EGFR-mutated metastatic NSCLC previously treated with EGFR TKIs.”

Source: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

Additional sources: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Grade 3 or 4 treatment-related adverse events

| Nivolumab plus chemotherapy | Chemotherapy |
| --- | --- |
| “44.7%” | “29.4%” |

Source: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

The enrollment target was reduced from 500 to 270 participants, and the estimated power with observed PFS events was 76%. The open-label study did not meet its primary PFS endpoint. Grade 3 or 4 TRAEs were reported in 44.7% versus 29.4%. The trial evaluates nivolumab, not ivonescimab.

Source: [Mok et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095864/)

<a id="heading-3.1.7"></a>

#### 3.1.7 COMPEL

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

Additional sources: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Geographic scope

> “global”

Source: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Allocation and masking

> “randomized, double-blind”

Source: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Progression pattern required for enrollment

> “non-central nervous system (CNS) progression”

Source: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Experimental and control oral treatments

> “osimertinib 80 mg”
> “placebo”

Source: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Investigator-assessed Progression-free Survival as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Primary outcome

> “investigator-assessed progression-free survival (PFS)”

Source: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

Additional sources: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Randomized participants per arm

> “49”

Source: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

Additional sources: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

Additional sources: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

Additional sources: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Median survival outcomes

| Outcome | Osimertinib plus chemotherapy, months | Placebo plus chemotherapy, months |
| --- | --- | --- |
| PFS | “8.4” | “4.4” |
| OS | “15.9” | “9.8” |

Source: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="topic-3.1.7.8.3-2"></a>

###### Overall survival hazard ratio: 95% confidence interval

> “0.42-1.23”

Source: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Grade 3 or higher adverse events

| Osimertinib plus chemotherapy | Placebo plus chemotherapy |
| --- | --- |
| “63%” | “46%” |

Source: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

There were 49 participants per arm, and eligibility required non-CNS progression. The OS hazard-ratio confidence interval included 1, so the numerical median OS difference does not establish an OS benefit. This study does not directly compare osimertinib continuation with ivonescimab.

Source: [Peled et al. (2025)](https://cris.bgu.ac.il/en/publications/compel-osimertinib-plus-platinum-based-chemotherapy-in-patients-w-2/)

<a id="heading-3.1.8"></a>

#### 3.1.8 TROPION-Lung05

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Molecularly selected study population

> “actionable genomic alterations”

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Snapshot data cutoff

> “The data cutoff date for the primary analysis (ie, when all patients had ≥9 months of follow-up after treatment initiation or had discontinued from the study, whichever occurred first) was December 14, 2022.”

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Trial phase

> “phase II”

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Required previous treatment classes

> “targeted therapy”
> “platinum-based chemotherapy”

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Datopotamab deruxtecan dose

> “6 mg/kg”

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Objective Response Rate as the Primary Endpoint

<a id="topic-3.1.8.6.1-1"></a>

###### Primary outcome

> “objective response rate”

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

Additional sources: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Treated participants

> “137”

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

Additional sources: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

Additional sources: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Genomic alteration groups

| EGFR-mutated | ALK-rearranged |
| --- | --- |
| “56.9%” | “24.8%” |

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Objective response rate

| Overall study population | EGFR-mutated subgroup |
| --- | --- |
| “35.8%” | “43.6%” |

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

###### Study-wide safety outcomes

| Safety outcome | Quoted percentage |
| --- | --- |
| Grade 3 or higher treatment-related adverse events | “28.5%” |
| Adjudicated treatment-related interstitial lung disease or pneumonitis | “3.6%” |
| Grade 5 interstitial lung disease or pneumonitis | “0.7%” |

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

The 137-participant population included multiple genomic subgroups; 56.9% had EGFR mutations. The overall ORR and safety percentages should not be presented as EGFR-specific estimates. The EGFR-subgroup ORR of 43.6% is not a randomized comparison with ivonescimab.

Source: [Sands et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11949215/)

<a id="heading-3.1.9"></a>

#### 3.1.9 Case report: malignant pleural effusion and acquired complex resistance

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

<a id="topic-3.1.9.1-1"></a>

###### Clinical question: acquired resistance

> “complex acquired resistance”

Source: [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

Additional sources: [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

Additional sources: [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Sequential ivonescimab regimens

> “ivonescimab monotherapy”
> “ivonescimab plus pemetrexed”

Source: [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Radiographic Disease Control as the Reported Outcome

Not applicable.

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

Not applicable.

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

Additional sources: [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

<a id="topic-3.1.9.8.2-1"></a>

###### Baseline age and EGFR alteration

> “A 55-year-old man”
> “EGFR exon 19 deletion”

Source: [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

###### Case report: malignant pleural effusion and acquired complex resistance

> “ivonescimab monotherapy, achieving disease control for nearly 5 months”

Source: [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

<a id="topic-3.1.9.8.5-1"></a>

###### Qualitative safety description

> “a manageable safety profile”

Source: [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary

This single-participant case cannot estimate a comparative treatment effect or establish that the reported resistance pattern predicts benefit. Disease control during monotherapy and subsequent combination treatment should not be conflated. The qualitative safety description does not provide an adverse-event rate.

Source: [Mo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753922/)

<a id="heading-3.1.10"></a>

#### 3.1.10 Case report: lung adenosquamous carcinoma after multiline therapy

<a id="heading-3.1.10.1"></a>

##### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

###### Clinical context

> “multi-line therapies”

Source: [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="heading-3.1.10.2"></a>

##### 3.1.10.2 Location and Study Date

<a id="topic-3.1.10.2-1"></a>

###### Initial imaging date

> “September 7, 2022”

Source: [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="heading-3.1.10.3"></a>

##### 3.1.10.3 Study Design

Additional sources: [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="heading-3.1.10.4"></a>

##### 3.1.10.4 Eligibility Criteria

Not applicable.

<a id="heading-3.1.10.5"></a>

##### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

###### Ivonescimab regimen

> “ivonescimab monotherapy”

Source: [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="heading-3.1.10.6"></a>

##### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

###### 3.1.10.6.1 Rationale for Using Radiographic Partial Response as the Reported Outcome

Not applicable.

<a id="heading-3.1.10.7"></a>

##### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

###### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

Not applicable.

<a id="heading-3.1.10.7.2"></a>

###### 3.1.10.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.10.8"></a>

##### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

###### 3.1.10.8.1 Participant Disposition

Additional sources: [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="heading-3.1.10.8.2"></a>

###### 3.1.10.8.2 Baseline Characteristics

<a id="topic-3.1.10.8.2-1"></a>

###### Baseline age, EGFR alterations, and PD-L1 expression

> “51-year-old male”
> “p.T790M and p.L858R”
> “TPS 5%”

Source: [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="heading-3.1.10.8.3"></a>

###### 3.1.10.8.3 Efficacy Results

<a id="topic-3.1.10.8.3-1"></a>

###### Radiographic response

> “rapid partial response (PR)”

Source: [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="topic-3.1.10.8.3-2"></a>

###### Case report: lung adenosquamous carcinoma after multiline therapy

> “sustained over six cycles with minimal toxicity.”

Source: [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="heading-3.1.10.8.4"></a>

###### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.10.8.5"></a>

###### 3.1.10.8.5 Safety Results

Additional sources: [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="heading-3.1.10.9"></a>

##### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

###### Summary

The report describes one participant with adenosquamous histology and multiple previous therapies. A response sustained over six cycles cannot establish an OS benefit, comparative efficacy, or the frequency of uncommon toxicity. The findings should not be generalized to all EGFR-mutated NSCLC.

Source: [Pan et al. (2025)](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1707096/full)

<a id="heading-3.1.11"></a>

#### 3.1.11 HARMONi-5

<a id="heading-3.1.11.1"></a>

##### 3.1.11.1 Objective

<a id="topic-3.1.11.1-1"></a>

###### Treatment-line objective

> “first- or second-line monotherapy”

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.2"></a>

##### 3.1.11.2 Location and Study Date

<a id="topic-3.1.11.2-1"></a>

###### Analysis data cutoff

> “October 5, 2022”

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.3"></a>

##### 3.1.11.3 Study Design

<a id="topic-3.1.11.3-1"></a>

###### Trial phase

> “Phase 1b”

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.4"></a>

##### 3.1.11.4 Eligibility Criteria

<a id="topic-3.1.11.4-1"></a>

###### Prior immunotherapy status

> “immunotherapy-naive NSCLC”

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.5"></a>

##### 3.1.11.5 Treatment

<a id="topic-3.1.11.5-1"></a>

###### One investigated dose cohort

> “20 mg/kg Q3W”

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.6"></a>

##### 3.1.11.6 Study Outcomes

<a id="heading-3.1.11.6.1"></a>

###### 3.1.11.6.1 Rationale for Using Objective Response Rate as a Primary Endpoint

<a id="topic-3.1.11.6.1-1"></a>

###### Primary outcomes

> “safety and objective response rate (ORR)”

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

Additional sources: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.11.7"></a>

##### 3.1.11.7 Statistical Analysis Description

<a id="heading-3.1.11.7.1"></a>

###### 3.1.11.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.11.7.1-1"></a>

###### Enrolled and treated participants

> “108”

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.7.2"></a>

###### 3.1.11.7.2 Description of Analysis Sets

Additional sources: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.8"></a>

##### 3.1.11.8 Results

<a id="heading-3.1.11.8.1"></a>

###### 3.1.11.8.1 Participant Disposition

Additional sources: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.8.2"></a>

###### 3.1.11.8.2 Baseline Characteristics

<a id="topic-3.1.11.8.2-1"></a>

###### Participants with PD-L1 tumor proportion score of at least 1%

> “68.5%”

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.8.3"></a>

###### 3.1.11.8.3 Efficacy Results

<a id="topic-3.1.11.8.3-1"></a>

###### Overall objective response rate

> “39.8%”

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.8.4"></a>

###### 3.1.11.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.11.8.5"></a>

###### 3.1.11.8.5 Safety Results

<a id="topic-3.1.11.8.5-1"></a>

###### Study-wide treatment-related adverse events

| Outcome | Quoted percentage |
| --- | --- |
| Grade 3 or higher TRAEs | “22.2%” |
| TRAEs leading to death, reported in squamous NSCLC | “2.8%” |

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.11.9"></a>

##### 3.1.11.9 Study Limitations

<a id="topic-3.1.11.9-1"></a>

###### Summary

This phase 1b evidence concerns monotherapy, not the chemotherapy combination evaluated in the pivotal trials. Grade 3 or higher TRAEs occurred in 22.2%, and TRAEs leading to death were reported in 2.8%. The monotherapy response estimate should not be substituted for post-TKI combination-treatment efficacy.

Source: [Wang et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37879536/)

<a id="heading-3.1.12"></a>

#### 3.1.12 AK112-101

<a id="heading-3.1.12.1"></a>

##### 3.1.12.1 Objective

<a id="topic-3.1.12.1-1"></a>

###### Primary clinical objective

> “safety and tolerability”

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.2"></a>

##### 3.1.12.2 Location and Study Date

<a id="topic-3.1.12.2-1"></a>

###### Study setting: Australia

> “six sites”

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="topic-3.1.12.2-2"></a>

###### Enrollment dates reported in the publication

| Date element | Quoted date |
| --- | --- |
| Enrollment start | “October 2, 2019” |
| Enrollment end in the abstract | “January 14, 2021” |
| Enrollment end in the results section | “June 14, 2021” |

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.3"></a>

##### 3.1.12.3 Study Design

<a id="topic-3.1.12.3-1"></a>

###### Phase 1a dose escalation study

> “Phase 1a dose escalation study of ivonescimab (AK112/SMT112)”

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="topic-3.1.12.3-2"></a>

###### Dose-escalation design

> “3+3+3”

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.4"></a>

##### 3.1.12.4 Eligibility Criteria

<a id="topic-3.1.12.4-1"></a>

###### Disease population

> “advanced solid tumors”

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.5"></a>

##### 3.1.12.5 Treatment

Additional sources: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.6"></a>

##### 3.1.12.6 Study Outcomes

<a id="heading-3.1.12.6.1"></a>

###### 3.1.12.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

Not applicable.

<a id="heading-3.1.12.7"></a>

##### 3.1.12.7 Statistical Analysis Description

<a id="heading-3.1.12.7.1"></a>

###### 3.1.12.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.12.7.1-1"></a>

###### Enrolled participants

> “51”

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.7.2"></a>

###### 3.1.12.7.2 Description of Analysis Sets

<a id="topic-3.1.12.7.2-1"></a>

###### Statistical approach

> “Descriptive statistics”

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.8"></a>

##### 3.1.12.8 Results

<a id="heading-3.1.12.8.1"></a>

###### 3.1.12.8.1 Participant Disposition

<a id="topic-3.1.12.8.1-1"></a>

###### Participants with at least one postbaseline tumor assessment

> “47”

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.8.2"></a>

###### 3.1.12.8.2 Baseline Characteristics

Additional sources: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.8.3"></a>

###### 3.1.12.8.3 Efficacy Results

<a id="topic-3.1.12.8.3-1"></a>

###### Antitumor activity among response-evaluable participants

| Confirmed objective response rate | Disease control rate |
| --- | --- |
| “25.5%” | “63.8%” |

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.8.4"></a>

###### 3.1.12.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.12.8.5"></a>

###### 3.1.12.8.5 Safety Results

<a id="topic-3.1.12.8.5-1"></a>

###### Maximum tolerated dose

> “The MTD of ivonescimab was 20 mg/kg every 2 weeks.”

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="topic-3.1.12.8.5-2"></a>

###### Grade 3 or higher treatment-related adverse events

> “27.5%”

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.12.9"></a>

##### 3.1.12.9 Study Limitations

<a id="topic-3.1.12.9-1"></a>

###### Summary

The study enrolled 51 participants with advanced solid tumors, with 47 contributing a postbaseline response assessment. Descriptive dose-escalation findings do not establish efficacy specifically in EGFR-mutated NSCLC. The publication gives different enrollment end dates in its abstract and results section; neither date has been silently substituted for the other. The maximum tolerated dose is specific to this study and schedule.

Source: [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

<a id="heading-3.1.13"></a>

#### 3.1.13 AK112-102

<a id="heading-3.1.13.1"></a>

##### 3.1.13.1 Objective

<a id="topic-3.1.13.1-1"></a>

###### Clinical pharmacology objectives

> “Safety, PK, and PD”

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-3.1.13.2"></a>

##### 3.1.13.2 Location and Study Date

Additional sources: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-3.1.13.3"></a>

##### 3.1.13.3 Study Design

<a id="topic-3.1.13.3-1"></a>

###### Study design

> “dose-escalation”

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-3.1.13.4"></a>

##### 3.1.13.4 Eligibility Criteria

<a id="topic-3.1.13.4-1"></a>

###### Disease population

> “advanced solid tumors”

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-3.1.13.5"></a>

##### 3.1.13.5 Treatment

Additional sources: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-3.1.13.6"></a>

##### 3.1.13.6 Study Outcomes

<a id="heading-3.1.13.6.1"></a>

###### 3.1.13.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

Not applicable.

<a id="heading-3.1.13.7"></a>

##### 3.1.13.7 Statistical Analysis Description

<a id="heading-3.1.13.7.1"></a>

###### 3.1.13.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.13.7.1-1"></a>

###### Planned and treated participants

| Quantity | Quoted count |
| --- | --- |
| Planned enrollment | “Fifty-four” |
| Treated participants | “59” |

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-3.1.13.7.2"></a>

###### 3.1.13.7.2 Description of Analysis Sets

<a id="topic-3.1.13.7.2-1"></a>

###### Statistical approach

> “descriptive statistics”

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-3.1.13.8"></a>

##### 3.1.13.8 Results

<a id="heading-3.1.13.8.1"></a>

###### 3.1.13.8.1 Participant Disposition

<a id="topic-3.1.13.8.1-1"></a>

###### Screened participants

> “93”

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-3.1.13.8.2"></a>

###### 3.1.13.8.2 Baseline Characteristics

<a id="topic-3.1.13.8.2-1"></a>

###### Representation of non-small-cell lung cancer

| Baseline characteristic | Quoted count and percentage |
| --- | --- |
| Participants with non-small-cell lung cancer, n (%) | “1 (1.7)” |

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-3.1.13.8.3"></a>

###### 3.1.13.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.13.8.4"></a>

###### 3.1.13.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.13.8.5"></a>

###### 3.1.13.8.5 Safety Results

<a id="topic-3.1.13.8.5-1"></a>

###### Treatment-related adverse events

| Outcome | Quoted percentage |
| --- | --- |
| Grade 3 or higher TRAEs | “23.7%” |
| Serious TRAEs | “11.9%” |

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="topic-3.1.13.8.5-2"></a>

###### Maximum tolerated dose finding

> “no maximum tolerated dose was reached.”

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/)

<a id="heading-3.1.13.9"></a>

##### 3.1.13.9 Study Limitations

<a id="topic-3.1.13.9-1"></a>

###### Summary

Only 1 of 59 participants, 1.7%, had NSCLC. These descriptive safety and pharmacology findings cannot establish efficacy for EGFR-mutated NSCLC. Unlike the Australian phase 1a study, this study did not reach a maximum tolerated dose; the results should not be merged into a single universal maximum-dose conclusion.

Source: [Wang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11925807/); [Frentzas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11033648/)

## Related pages
- [Ivonescimab: EGFR-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Terms and abbreviations](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/terms-and-abbreviations.md)
- [Ivonescimab: EGFR-mutated non-small-cell lung cancer](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/executive-summary.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Product information and disease description](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/product-information-and-disease-description.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: Economic information and modeling report](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/economics.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: References](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/references) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/references.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: prevalence by geography](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/prevalence) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/prevalence.md)
- [Ivonescimab in EGFR-mutated non-small-cell lung cancer: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/cost-effectiveness-analyses.md)
